Plaquverazon Overdose

sponsored
Was this medicine useful for you?

What happens if I overdose Plaquverazon?

Seek emergency medical attention if you think you have used too much of this medicine, or if anyone has accidentally swallowed it.

Overdose symptoms may include nausea, vomiting, lost appetite, tiredness, trouble breathing, joint/muscle pain, feeling light-headed, or fainting.

Overdose of Plaquverazon in details

infoWhen a dose is taken in higher dose than the recommended doses, it is called Overdose. Overdose always needs a clinical supervision. Any medicine or drug when consumed in Overdose produces untoward side effects on one or various organs in the body. A medicine is excreted in the kidney or metabolized in the liver most of the times. This process goes without any hurdles when taken in normal dose, but when taken in an overdose, the body is not able to metabolize it or send it out properly which causes the effects of anoverdose.
sponsored

Gel: Use above the recommended dose may cause elevated serum calcium which should rapidly subside when treatment is discontinued.

Excessive prolonged use of topical corticosteroids may suppress the pituitary-adrenal functions, resulting in secondary adrenal insufficiency which is usually reversible. In such cases, symptomatic treatment is indicated.

In case of chronic toxicity, the corticosteroid treatment must be discontinued gradually.

It has been reported that due to misuse, 1 patient with extensive erythrodermic psoriasis treated with Plaquverazon ointment 240 g weekly (maximum dose 100 g weekly) for 5 months developed Cushing’s syndrome and pustular psoriasis after abruptly stopping treatment.

What should I avoid while taking Plaquverazon?

Do not use on broken or infected skin. Also avoid using the medicine in open wounds. If this medicine gets in your eyes, nose, mouth, rectum, or vagina, rinse with water.

Do not use more than one topical steroid medicine without your doctor's advice.

Avoid having your hair colored within 12 hours before or after you apply Plaquverazon to your scalp.

Avoid exposure to sunlight or tanning beds. This medicine can make you sunburn more easily. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.

Plaquverazon warnings

infoWarnings are a mix of Precautions. Contraindications and interactions and serious harmful effects associated with the medicine intake. A diabetic or Hypertensive patient need to be warned about few drug interactions. A known hypersensitivity patient needs to be careful about the reactions or anaphylactic shock. A pregnant woman or a breastfeeding woman should be warned of certain medications. A Hepatitis [liver disease] patient or a cardiac patient should avoid few drugs.
sponsored

Hypercalcemia and Hypercalciuria

Hypercalcemia and hypercalciuria have been observed with use of Plaquverazon® Ointment. If hypercalcemia or hypercalciuria develop, treatment should be discontinued until parameters of calcium metabolism have normalized. In the trials that included assessment of the effects of Plaquverazon® Ointment on calcium metabolism, such testing was done after 4 weeks of treatment. The effects of Plaquverazon® Ointment on calcium metabolism following treatment durations of longer than 4 weeks have not been evaluated.

Effects on Endocrine System

Plaquverazon® Ointment can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of treatment. Factors that predispose a patient to HPA axis suppression include the use of high-potency corticosteroids, large treatment surface areas, prolonged use, concomitant use of more than one corticosteroid-containing product, use of occlusive dressings, altered skin barrier, liver failure, and young age. Evaluation for HPA axis suppression may be done by using the cosyntropin stimulation test.

In a trial evaluating the effects of Plaquverazon®

Topical Suspension and Plaquverazon® Ointment on the HPA axis, 32 adult subjects were treated with Plaquverazon®

Topical Suspension on the scalp and Plaquverazon® Ointment on the body. Adrenal suppression was identified in 5 of 32 subjects (15.6%) after 4 weeks of treatment. The effects of Plaquverazon® Ointment on the HPA axis following treatment durations of longer than 4 weeks have not been adequately studied.

If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid.

Cushing's syndrome and hyperglycemia may also occur due to the systemic effects of topical corticosteroids. These complications are rare and generally occur after prolonged exposure to excessively large doses, especially of high-potency topical corticosteroids.

Pediatric patients may be more susceptible to systemic toxicity due to their higher skin surface to body mass ratios.

Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure.

Allergic Contact Dermatitis with

Topical Corticosteroids

Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.

Allergic Contact Dermatitis with

Topical Calcipotriene

Allergic contact dermatitis has been observed with use of topical calcipotriene. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.

Skin Irritation

If irritation develops, treatment with Plaquverazon® Ointment should be discontinued and appropriate therapy instituted.

Risk of Ultraviolet Light Exposure

Patients who apply Plaquverazon® Ointment to exposed skin should avoid excessive exposure to either natural or artificial sunlight, including tanning booths, sun lamps, etc. Physicians may wish to limit or avoid use of phototherapy in patients who use Plaquverazon® Ointment.

What should I discuss with my healthcare provider before taking Plaquverazon?

You should not use Plaquverazon if you are allergic to Betamethasone (Plaquverazon) or calcipotriene.

To make sure this medicine is safe for you, tell your doctor if you have:

  • high levels of calcium in your blood (hypercalcemia);

  • a history of kidney stones;

  • liver or kidney disease;

  • severe forms of psoriasis (with pus, skin peeling, severe redness);

  • a skin infection; or

  • if you are receiving UV light treatments (phototherapy).

It is not known whether Plaquverazon will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

It is not known whether Betamethasone (Plaquverazon) and calcipotriene topical passes into breast milk or if it could harm a nursing baby. Do not apply this medicine to your breasts if you are breast-feeding a baby.

Do not use Plaquverazon on a child without a doctor's advice. Children can absorb larger amounts of steroid medicine through the skin and may be more likely to have side effects. Steroid medicine can also affect growth in children. Talk with your doctor if you think your child is not growing at a normal rate while using this medicine.

Plaquverazon is not approved for use by anyone younger than 12 years old.

Plaquverazon precautions

infoCertain people who are very sick or very old or who are sensitive show an exacerbation of side effect of the drug which can turn dangerous at times. So, it is very important to remember the precautions while taking the medicine. Pregnancy and Breastfeeding are also special categories wherein extra care or precaution is needed when taking a drug. Few patients may have a hypersensitivity reaction to few medications, and that can be life-threatening rarely. Penicillin hypersensitivity is one example. Diarrhea, rashes are few other symptoms which need a watch. A patient with other co-existing diseases like liver disease, heart disease, kidney disease should take special precautions.
sponsored

Hypercalcemia and Hypercalciuria

Hypercalcemia and hypercalciuria have been observed with use of Plaquverazon® Ointment. If hypercalcemia or hypercalciuria develop, treatment should be discontinued until parameters of calcium metabolism have normalized. In the trials that included assessment of the effects of Plaquverazon® Ointment on calcium metabolism, such testing was done after 4 weeks of treatment. The effects of Plaquverazon® Ointment on calcium metabolism following treatment durations of longer than 4 weeks have not been evaluated.

Effects on Endocrine System

Plaquverazon® Ointment can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of treatment. Factors that predispose a patient to HPA axis suppression include the use of high-potency corticosteroids, large treatment surface areas, prolonged use, concomitant use of more than one corticosteroid-containing product, use of occlusive dressings, altered skin barrier, liver failure, and young age. Evaluation for HPA axis suppression may be done by using the cosyntropin stimulation test.

In a trial evaluating the effects of Plaquverazon®

Topical Suspension and Plaquverazon® Ointment on the HPA axis, 32 adult subjects were treated with Plaquverazon®

Topical Suspension on the scalp and Plaquverazon® Ointment on the body. Adrenal suppression was identified in 5 of 32 subjects (15.6%) after 4 weeks of treatment. The effects of Plaquverazon® Ointment on the HPA axis following treatment durations of longer than 4 weeks have not been adequately studied.

If HPA axis suppression is documented, gradually withdraw the drug, reduce the frequency of application, or substitute with a less potent corticosteroid.

Cushing's syndrome and hyperglycemia may also occur due to the systemic effects of topical corticosteroids. These complications are rare and generally occur after prolonged exposure to excessively large doses, especially of high-potency topical corticosteroids.

Pediatric patients may be more susceptible to systemic toxicity due to their higher skin surface to body mass ratios.

Use of more than one corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure.

Allergic Contact Dermatitis with

Topical Corticosteroids

Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.

Allergic Contact Dermatitis with

Topical Calcipotriene

Allergic contact dermatitis has been observed with use of topical calcipotriene. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.

Skin Irritation

If irritation develops, treatment with Plaquverazon® Ointment should be discontinued and appropriate therapy instituted.

Risk of Ultraviolet Light Exposure

Patients who apply Plaquverazon® Ointment to exposed skin should avoid excessive exposure to either natural or artificial sunlight, including tanning booths, sun lamps, etc. Physicians may wish to limit or avoid use of phototherapy in patients who use Plaquverazon® Ointment.

What happens if I miss a dose of Plaquverazon?

infoWhen you miss a dose, you should take it as soon as you remember, but you should take care that it should be well spaced from the next dose. You should not take an extra dose at the time of the second dose as it will become a double dose. The double dose can give unwanted side effects, so be careful. In chronic conditions or when you have a serious health issue, if you miss a dose, you should inform your health care provider and ask his suggestion.

Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and wait until your next regularly scheduled dose. Do not use extra medicine to make up the missed dose.



References

  1. DailyMed. "CALCIPOTRIENE HYDRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. DailyMed. "BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  3. DrugBank. "Calcipotriol". http://www.drugbank.ca/drugs/DB02300 (accessed September 17, 2018).

Reviews

Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 13 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2020 ndrugs.com All Rights Reserved